Fig. 1.

Potential for immunogenicity in therapeutic mAbs.

In a chimeric antibody, V_H and V_L (which contains the CDR) are the sequences derived from a mouse antibody; approximately 65% of the sequence is from a human antibody. On the other hand, a humanized antibody includes only the CDR of a mouse antibody. Over 90% of the antibody sequence is from human. CDR, complementarity determining region; C_H and C_L, constant regions of the heavy and light chains; V_H and V_L, variable regions of the heavy and light chains.